• If you are trying to figure out whether Healthpeak Properties is reasonably priced or offering a margin of safety, this article walks through what the current share price might be implying.
• The stock last closed at US$17.63, with returns of 1.9% over the past week, 2.3% over the past month, 8.8% year to date, and a 7.9% decline over the last year. This may leave you wondering whether the recent moves reflect changing risk or opportunity.
• Recent news flow around Healthpeak Properties has mainly focused on its position as a healthcare focused REIT and how investors are thinking about listed real estate in general, rather than on any single company specific event. That context can help explain why shorter term returns look different to the 3 year and 5 year figures, which show declines of 12.3% and 24.0% respectively.
• Healthpeak Properties currently scores 5 out of 6 on our valuation checks for being undervalued, and you can see the breakdown in our valuation score. Next we will look at how different valuation approaches line up and finish with a method that can give you a richer view of what the stock might be worth.

Approach 1: Healthpeak Properties Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future adjusted funds from operations and then discounting those cash flows back to today’s dollars.

For Healthpeak Properties, the model uses last twelve months free cash flow of about $1.29b and a 2 Stage Free Cash Flow to Equity approach based on adjusted funds from operations. Analysts provide explicit forecasts out to 2030, with projected free cash flow of $1.26b in that year. Estimates for 2026 to 2035 are blended from analyst inputs for the nearer years and extrapolated figures for the later years.

When all those projected cash flows are discounted back, the DCF model arrives at an estimated intrinsic value of about $31.90 per share. Compared with the recent share price of $17.63, this implies a 44.7% discount. This indicates that the shares are trading materially below this cash flow based estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Healthpeak Properties is undervalued by 44.7%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Healthpeak Properties Price vs Sales

For profitable companies where revenue is a key driver, the P/S ratio can be a useful way to see what investors are paying for each dollar of sales, especially for REITs where accounting earnings can be influenced by non cash items.

What counts as a “normal” P/S ratio often reflects how quickly a business is expected to grow and how risky those cash flows appear. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty usually points to a lower one.

Healthpeak Properties currently trades on a P/S of 4.34x. That is below both the Health Care REITs industry average of 7.01x and the broader peer group average of 9.63x, which might initially make the stock look inexpensive compared to other names in the space.

Simply Wall St’s Fair Ratio for Healthpeak Properties is 5.72x. This proprietary measure estimates what the P/S ratio could be given factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it adjusts for these fundamentals, it can be more informative than a simple comparison to industry or peer averages.

Comparing the Fair Ratio of 5.72x with the actual P/S of 4.34x suggests that the shares are pricing in a lower multiple than this model implies.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Healthpeak Properties Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives let you set out your own story for Healthpeak Properties, tie that story to specific assumptions for future revenue, earnings and margins, translate those assumptions into a fair value, and then compare that fair value to the current price inside Simply Wall St's Community page. Narratives update as new news or earnings arrive. One investor might build a cautious view around a fair value near US$16.00, while another leans into a more upbeat thesis closer to US$26.71. You can see both side by side and decide which version of the story you agree with.

For Healthpeak Properties, however, we’ll make it really easy for you with previews of two leading Healthpeak Properties Narratives:

Each one connects a different story about demand, risk and future earnings to a specific fair value estimate, so you can quickly see which set of assumptions feels closer to your own view.

Fair value used in this narrative: US$20.17 per share

Gap to this fair value: 12.6% below the narrative estimate based on the last close of US$17.63

Revenue growth assumption: 2.89% per year

• Analysts link demand for outpatient care, senior housing and life science space to steady revenue and margin assumptions for Healthpeak Properties.
• The narrative expects modest improvements in profit margins and earnings by 2028, supported by operational efficiencies and a concentrated, higher quality portfolio.
• Key risks include tenant credit quality, capital market conditions and regulatory changes that could affect occupancy, rent collection and the ability to reinvest or grow dividends.

Fair value used in this narrative: US$16.00 per share

Gap to this fair value: 10.2% above the narrative estimate based on the last close of US$17.63

Revenue growth assumption: 1.87% per year

• This narrative leans on the more cautious analyst assumptions, tying fair value to the lowest price target and an outlook that treats recent conditions as a ceiling rather than a starting point.
• It highlights potential pressure from life science tenants that rely heavily on external funding, concentrated exposure to a handful of markets and development execution risks.
• Higher interest costs, refinancing needs and regulatory or reimbursement changes are framed as ongoing overhangs that could limit growth in earnings and cash flow.

Taken together, these two narratives bracket a fair value range of about US$16.00 to US$20.17 per share based on different assumptions around growth, margins and risk. If you find yourself aligning more with one set of assumptions than the other, that can be a useful starting point for deciding whether the current price of US$17.63 feels demanding, comfortable or conservative for your own investment style.

Do you think there's more to the story for Healthpeak Properties? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.